After the disclosure of the first quarterly report, the performance of A-share listed companies can be described as “two days of ice and fire”. Some beneficiary industries are in high prosperity, and the performance of companies standing on the track and tuyere frequently “burst the table”, such as Andon Health Co.Ltd(002432) , Guangzhou Wondfo Biotech Co.Ltd(300482) , Hangzhou Alltest Biotech Co.Ltd(688606) ; Ganfeng Lithium Co.Ltd(002460) , Youngy Co.Ltd(002192) etc. in lithium industry; However, the performance of some stars and white horse stocks is not satisfactory. For example, the net profit of “Youmao” Yihai Kerry Arawana Holdings Co.Ltd(300999) decreased by more than 90% in the first quarter, the net profit of “glove Mao” Intco Medical Technology Co.Ltd(300677) decreased by about 98%, and the net profit of lithium battery leader Contemporary Amperex Technology Co.Limited(300750) increased without increasing profit, which decreased by nearly 24% in the first quarter.
Andon Health Co.Ltd(002432) soared 375 times in the first quarter
the first quarter report of 2022 disclosed on Andon Health Co.Ltd(002432) 29 shows that in the first quarter, the company achieved an operating revenue of 21.737 billion yuan, an increase of 664679% year-on-year; The net profit attributable to shareholders of listed companies was 14.312 billion yuan, a year-on-year increase of 3752735%; The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was 14.345 billion yuan, a year-on-year increase of 75666914%.
The performance forecast disclosed by the company recently shows that in the first quarter, the company is expected to realize a net profit attributable to the owners of the parent company of 14-16 billion yuan, an increase of 3670743% – 4196563% over the same period of the previous year. This means that the company’s net profit in the first quarter met expectations.
After the disclosure of the performance forecast, Andon Health Co.Ltd(002432) rose the limit for three consecutive trading days from April 12 to April 14, but after hitting a record high on April 15, it staged a “sky floor” trend and finally closed at the limit. On April 29, the stock rose again. From the perspective of lengthening the cycle, the stock has risen more than 16 times to a record high of 99.12 yuan since the low of 5.8 yuan at the end of October 2021.
For the reasons for the growth of performance in the first quarter, Andon Health Co.Ltd(002432) said that due to the development of the epidemic in the United States, the local demand for covid-19 antigen detection kit products increased significantly. During the reporting period, ihealth US subsidiary of the company sold ihealth covid-19 antigen detection kit products through its own channels and Amazon platform, and signed major contracts and orders with customers. The increase in sales revenue of this product has made an important contribution to the company’s performance during the reporting period.
However, the company also indicated that the performance growth in the reporting period was mainly driven by the substantial growth in the sales of covid-19 antigen detection kit products. Due to the unpredictability of epidemic development, the promotion of vaccination plan, the change of market demand and the change of market competition environment, there is still some uncertainty whether the future performance can continue to maintain high-speed growth.
in addition to Andon Health Co.Ltd(002432) , Guangzhou Wondfo Biotech Co.Ltd(300482) , Hangzhou Alltest Biotech Co.Ltd(688606) and other covid-19 testing companies, the first quarter performance is also quite “bright”
For example, Guangzhou Wondfo Biotech Co.Ltd(300482) achieved an operating revenue of 2.625 billion yuan in the first quarter, an increase of 276.87% over the same period of the previous year; The net profit attributable to the shareholders of the listed company was 904 million yuan, an increase of 481.32% over the same period of last year, with a significant increase of about 124 times month on month.
Hangzhou Alltest Biotech Co.Ltd(688606) in the first quarter, the operating revenue was 2.099 billion yuan, with a year-on-year increase of 628.17%; The net profit attributable to shareholders of listed companies was 1.049 billion yuan, a year-on-year increase of 598.18%.
Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) in the first quarter, the operating revenue was 2.487 billion yuan, a year-on-year increase of 267.41%; The net profit attributable to listed shareholders was 30.705 billion yuan, a year-on-year increase of 13.89%.
The main reason for the sharp increase in the performance of the above companies in the first quarter is that they benefited from the sharp increase in the demand for covid-19 testing products. For example, Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) said that since January 2022, the covid-19 epidemic in Omicron overseas has been repeated, the market demand for covid-19 antigen detection kit has increased, and the company’s export orders for covid-19 antigen detection kit have increased significantly year-on-year Guangzhou Wondfo Biotech Co.Ltd(300482) said, Guangzhou Wondfo Biotech Co.Ltd(300482) said that in the first quarter, the company actively helped the global covid-19 anti epidemic and epidemic prevention, and covid-19 testing business contributed significantly to performance growth. Covid-19 series testing reagents of the company have been sold in more than 100 countries and regions in Europe, Asia, Latin America and the Middle East.
several lithium mining companies’ performance increased significantly
Benefiting from the high prosperity of the new energy vehicle industry, the prices of upstream materials and products continued to rise, and the net profits of many lithium mining companies also increased significantly in the first quarter.
For example, the quarterly report of Youngy Co.Ltd(002192) shows that during the reporting period, the company achieved an operating revenue of 478 million yuan, an increase of 339.46% year-on-year; The net profit attributable to shareholders of listed companies was 254 million yuan, an increase of about 140% year-on-year.
The company said that due to the impact of macro policies and increased market demand, the prosperity of the new energy industry continued to improve, the prices of upstream materials and products in the lithium battery industry continued to rise sharply, the demand for lithium battery materials and lithium battery equipment continued to increase, and the operating revenue and profit of the company’s lithium concentrate, lithium salt and lithium battery equipment increased significantly.
Chengxin Lithium Group Co.Ltd(002240) in the first quarter, the operating revenue was 1.687 billion yuan, an increase of 212.59% year-on-year; The net profit attributable to shareholders of listed companies was 1.07 billion yuan, a year-on-year increase of 900.96%. For the reasons for the substantial growth of performance in the first quarter, the company said that the rapid development of new energy industry in the reporting period, the strong growth of downstream customers’ demand for lithium salt, the continuous rise of lithium salt product prices, and the sharp rise of the company’s lithium salt business profit compared with the same period of last year.
Ganfeng Lithium Co.Ltd(002460) achieved an operating revenue of 5.365 billion yuan in the first quarter, a year-on-year increase of 233.91%; The net profit attributable to shareholders of listed companies was 3.525 billion yuan, a year-on-year increase of 640.41% Everbright Securities Company Limited(601788) pointed out that the company’s performance in the first quarter hit another record high. In March, the company realized a net profit attributable to the parent company of about 2.125 billion yuan, more than the sum of January and February.
The company’s excellent performance in the first quarter was mainly due to the sharp increase in the price of lithium salt products compared with the previous year. In the first quarter of 2022, the average prices of battery grade lithium carbonate and lithium hydroxide were 400000 yuan / ton and 348000 yuan / ton respectively, with a year-on-year increase of 467% and 492%.
Tianqi Lithium Corporation(002466) in the first quarter, the operating revenue was 5.257 billion yuan, a year-on-year increase of 481.41%; The net profit attributable to shareholders of listed companies was 3.328 billion yuan, compared with a loss of 248 million yuan in the same period of last year.
Boosted by the large increase in performance in the first quarter, the share prices of many lithium mining companies have performed strongly recently. For example, Youngy Co.Ltd(002192) has risen the limit for three consecutive trading days this week, Chengxin Lithium Group Co.Ltd(002240) , Tianqi Lithium Corporation(002466) and Ganfeng Lithium Co.Ltd(002460) have risen by 30.4%, 28.6% and 20% respectively in the past three days.
several star stocks performed poorly
In the first quarter, the performance of several white horse star stocks was poor. For example, the net profit of “Youmao” Yihai Kerry Arawana Holdings Co.Ltd(300999) in the first quarter decreased by 92.7%, the net profit of “glove Mao” Intco Medical Technology Co.Ltd(300677) decreased by about 98%, and the phenomenon of “increasing income without increasing profit” appeared in “ningwang”, and the net profit decreased by 23.6%.
Yihai Kerry Arawana Holdings Co.Ltd(300999) yesterday disclosed the first quarter report of 2022, which showed that the company achieved a revenue of 56.536 billion yuan in the first quarter, a year-on-year increase of 10.68%; The net profit attributable to shareholders of listed companies was 114 million yuan, a year-on-year decrease of 92.71%; The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was 830 million yuan, a year-on-year decrease of 56.9%.
As for the reasons for the change of the company’s performance, Yihai Kerry Arawana Holdings Co.Ltd(300999) said that in the first quarter, affected by the expected soybean production due to the drought in South America and the conflict between Russia and Ukraine, the prices of the company’s main raw materials such as soybean, soybean oil and palm oil increased rapidly and sharply, resulting in a sharp rise in product costs. Although the company raised the prices of some products, it did not fully cover the rise in raw material costs, The gross profit margin of the company’s main products decreased significantly year-on-year. In addition, due to the impact of the multi-point spread of the epidemic in China on logistics and transportation, terminal sales, catering, etc., combined with the weak economy, sluggish consumption and intensified market competition, the sales volume of kitchen food of the company decreased year-on-year in the first quarter of 2022, and the profits of medium and high-end retail products were greatly affected.
Yesterday, Contemporary Amperex Technology Co.Limited(300750) also disclosed the first quarter report of 2022. In the first quarter, the company achieved an operating revenue of 48.678 billion yuan, a year-on-year increase of 153.97%; The net profit attributable to shareholders of listed companies was 1.493 billion yuan, a year-on-year decrease of 23.62%; The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was 977 million yuan, a year-on-year decrease of 41.57%. The company experienced the phenomenon of “increasing income without increasing profit” in the first quarter.
Insiders said that the decline in net profit of Contemporary Amperex Technology Co.Limited(300750) in the first quarter was mainly due to short-term factors. The sharp rise in the price of lithium carbonate and other raw materials caused the rise in the cost of lithium battery, putting pressure on the company’s performance. At present, although the price of lithium carbonate materials remains high in the short term, the Contemporary Amperex Technology Co.Limited(300750) fundamentals are good, and the resource layout advantage in the upstream of the industrial chain is obvious Contemporary Amperex Technology Co.Limited(300750) Secretary also said that the upstream price increase has slowed down, and the demand is still very strong. He is still optimistic about the development prospects of the industry and the company.
Intco Medical Technology Co.Ltd(300677) the first quarter report shows that the company achieved an operating revenue of 2.288 billion yuan in the first quarter, a year-on-year decrease of 66.03%; The net profit attributable to shareholders of listed companies was 83.493 million yuan, a year-on-year decrease of 97.77%.
The company pointed out in its annual report that in the first quarter of 2021, the demand and price of gloves reached the peak level. In the face of this huge market demand, a number of glove enterprises around the world have expanded their production capacity to a certain extent. At the same time, as the epidemic situation in various countries is gradually controlled, as well as the R & D and promotion of vaccines and drugs, the epidemic situation is gradually controlled, the demand for gloves is gradually normalized, and it takes a certain time to digest the inventory accumulated in different channels. Due to the expansion of production capacity and the gradual return of demand to a stable state, the market is facing a situation of phased supply exceeding demand, and the price also continues to fall. At present, the sales price of some channels is close to the pre epidemic level. Moreover, due to the high cost of raw materials and energy and the re imposition of U.S. tariffs, the industry is facing both opportunities and challenges. The company will continue and quickly adjust its business strategy in line with market changes.
